Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes

Biochemical and Biophysical Research Communications

Volumn 357, Issue 4, 2007, Pages 847-853

  Fyrberg, Anna ^a   Albertioni, Freidoun ^b   Lotfi, Kourosh ^a,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 Nucleotidase; Cell proliferation; Deoxycytidine kinase; Deoxyguanosine kinase; Deoxynucleoside analogue; Resistance

Indexed keywords

2 FLUOROARABINOSYLADENINE; 5' NUCLEOTIDASE; ADENINE DERIVATIVE; CLADRIBINE; CLOFARABINE; CYTARABINE; DEOXYCYTIDINE KINASE; DEOXYGUANOSINE KINASE; GUANINE ARABINOSIDE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CONTROLLED STUDY; CYTOTOXICITY; DEPHOSPHORYLATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PHOSPHORYLATION; PRIORITY JOURNAL;

ANIMALS; CELL CYCLE; DEOXYCYTIDINE KINASE; DEOXYRIBONUCLEOSIDES; ENZYME ACTIVATION; HUMANS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 34247892175     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.03.176     Document Type: Article

References (30)

1. Keszler G., Spasokoukotskaja T., Csapo Z., Talianidis I., Eriksson S., Staub M., and Sasvari-Szekely M. Activation of deoxycytidine kinase in lymphocytes is calcium dependent and involves a conformational change detectable by native immunostaining. Biochem. Pharmacol. 67 (2004) 947-955
2. Arner E.S., and Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol. Ther. 67 (1995) 155-186
3. Hengstschlager M., Denk C., and Wawra E. Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control. FEBS Lett. 321 (1993) 237-240
4. Csapo Z., Sasvari-Szekely M., Spasokoukotskaja T., Talianidis I., Eriksson S., and Staub M. Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. Biochem. Pharmacol. 61 (2001) 191-197
5. Spasokoukotskaja T., Sasvari-Szekely M., Keszler G., Albertioni F., Eriksson S., and Staub M. Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur. J. Cancer 35 (1999) 1862-1867
6. Zhu C., Johansson M., Permert J., and Karlsson A. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines. J. Biol. Chem. 273 (1998) 14707-14711
7. Lotfi K., Mansson E., Spasokoukotskaja T., Pettersson B., Liliemark J., Peterson C., Eriksson S., and Albertioni F. Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin. Cancer Res. 5 (1999) 2438-2444
8. Bai L., Yamaguchi M., Tatsumi M., Kon K., and Brautigam M. Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-d-arabinofuranosyl-2-fluoroadenine. J. Cancer Res. Clin. Oncol. 124 (1998) 367-373
9. Mansson E., Spasokoukotskaja T., Sallstrom J., Eriksson S., and Albertioni F. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res. 59 (1999) 5956-5963
10. Lotfi K., Mansson E., Peterson C., Eriksson S., and Albertioni F. Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-d-arabinofuranosylguanine cytotoxicity. Biochem. Biophys. Res. Commun. 293 (2002) 1489-1496
11. Galmarini C.M., Jordheim L., and Dumontet C. Role of IMP-selective 5′-nucleotidase (cN-II) in hematological malignancies. Leuk. Lymphoma 44 (2003) 1105-1111
12. Dumontet C., Fabianowska-Majewska K., Mantincic D., Callet Bauchu E., Tigaud I., Gandhi V., Lepoivre M., Peters G.J., Rolland M.O., Wyczechowska D., Fang X., Gazzo S., Voorn D.A., Vanier-Viornery A., and MacKey J. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br. J. Haematol. 106 (1999) 78-85
13. Lotfi K., Mansson E., Chandra J., Wang Y., Xu D., Knaust E., Spasokoukotskaja T., Liliemark E., Eriksson S., and Albertioni F. Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide. Br. J. Haematol. 113 (2001) 339-346
14. Carson D.A., Wasson D.B., Taetle R., and Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62 (1983) 737-743
15. Galmarini C.M., Graham K., Thomas X., Calvo F., Rousselot P., El Jafaari A., Cros E., Mackey J.R., and Dumontet C. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 98 (2001) 1922-1926
16. Ives D.H., Durham J.P., and Tucker V.S. Rapid determination of nucleoside kinase and nucleotidase activities with tritium-labeled substrates. Anal. Biochem. 28 (1969) 192-205
17. Rampazzo C., Mazzon C., Reichard P., and Bianchi V. 5′-Nucleotidases: specific assays for five different enzymes in cell extracts. Biochem. Biophys. Res. Commun. 293 (2002) 258-263
18. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
19. Vindelov L.L., and Christensen I.J. A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry 11 (1990) 753-770
20. Spasokoukotskaja T., Sasvari-Szekely M., Keszler G., Albertioni F., Eriksson S., and Staub M. Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur. J. Cancer 35 13 (1999) 1862-1867
21. Rylova S.N., Albertioni F., Flygh G., and Eriksson S. Activity profiles of deoxynucleoside kinases and 5′-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochem. Pharmacol. 69 6 (2005) 951-960
22. Mansson E., Flordal E., Liliemark J., Spasokoukotskaja T., Elford H., Lagercrantz S., Eriksson S., and Albertioni F. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem. Pharmacol. 65 (2003) 237-247
23. Rodriguez Jr. C.O., and Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 59 (1999) 4937-4943
24. Hunsucker S.A., Mitchell B.S., and Spychala J. The 5′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol. Ther. 107 (2005) 1-30
25. Hunsucker S.A., Spychala J., and Mitchell B.S. Human cytosolic 5′-nucleotidase I: characterization and role in nucleoside analog resistance. J. Biol. Chem. 276 (2001) 10498-10504
26. Galmarini C.M., Thomas X., Graham K., El Jafaari A., Cros E., Jordheim L., Mackey J.R., and Dumontet C. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br. J. Haematol. 122 (2003) 53-60
27. Pesi R., Turriani M., Allegrini S., Scolozzi C., Camici M., Ipata P.L., and Tozzi M.G. The bifunctional cytosolic 5′-nucleotidase: regulation of the phosphotransferase and nucleotidase activities. Arch. Biochem. Biophys. 312 (1994) 75-80
28. Johnson M.A., and Fridland A. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36 (1989) 291-295
29. Lofgren C., Hjortsberg L., Blennow M., Lotfi K., Paul C., Eriksson S., and Albertioni F. Mechanisms of cross-resistance between nucleoside analogues and vincristine or daunorubicin in leukemic cells. Biochem. Biophys. Res. Commun. 320 (2004) 825-832
30. Gazziola C., Ferraro P., Moras M., Reichard P., and Bianchi V. Cytosolic high K(m) 5′-nucleotidase and 5′(3′)-deoxyribonucleotidase in substrate cycles involved in nucleotide metabolism. J. Biol. Chem. 276 (2001) 6185-6190